About Us
Our Business
Investors
Media
Community
Sustainability
Careers
Contact
Menu
India
USA
UK
South Africa
Australia
Philippines
Germany
Netherlands
Mexico
Brazil
Canada
Switzerland
Close
About Us
Overview
The Lupin Story
Our Purpose
Our Values
Our Leadership
Compliance, Ethics and Governance
Global Presence
Our Manufacturing Approach
Quality in Action
Our Science
Awards and Recognitions
Our Business
Overview
Global Generics
Emerging Markets
India
Specialty and Innovation
Biosimilars
Our Adjacencies
Investors
Overview
Financials
Reports and Filings
Committees of the Board
Code of Conduct
Policies
Shareholder Information
Memorandum and Articles of Association
Employee Stock Option Schemes
News and Events
Business Responsibility
Analyst Coverage
Investor FAQs
Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
Media
Overview
Press Releases
Media Coverage
Perspectives
Media Kit
Community
Sustainability
Overview
ESG Framework
ESG Goals and Progress
Key Highlights
ESG Ratings
ESG Governance
Careers
Contact
About Us
Our Business
Investors
Media
Community
Sustainability
Careers
Contact
Overview
The Lupin Story
Our Purpose
Our Values
Our Leadership
Compliance, Ethics and Governance
Global Presence
Our Manufacturing Approach
Quality in Action
Our Science
Awards and Recognitions
+91 22 6640 2323
info@lupin.com
Press Releases
Lupin receives FDA approval for its Oral Contraceptive VyfemlaTM Tablets Generic of Ovcon® 35 Tablets
Product Finder
